Healius Limited (ASX:HLS)

Market Cap	726.13M
Revenue (ttm)	1.34B
Net Income (ttm)	-151.20M
Shares Out	726.13M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	51.15
Dividend	0.41 (41.30%)
Ex-Dividend Date	May 9, 2025

Volume	6,502,649
Average Volume	2,134,960
Open	1.0200
Previous Close	1.0000
Day's Range	0.9950 - 1.0400
52-Week Range	0.6620 - 1.6350
Beta	0.37
RSI	69.31
Earnings Date	Nov 19, 2025

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 8,224
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.